Steven Arthur George

This is why none of my American friends and family know the benefits of CBD! "Medicinal Cannabis: Comparing FDA and ANVISA's Approach to Doctor-Led Oversight" The disparity between how the FDA in the United States and ANVISA in Brazil approach the regulation of medicinal cannabis highlights key differences in both policy frameworks and cultural perspectives on healthcare governance. In the U.S., the FDA classifies cannabis as a Schedule I substance under the Controlled Substances Act, which means it’s federally deemed to have "no accepted medical use." This restricts medical professionals from prescribing it in the traditional sense and means the FDA doesn’t endorse its medicinal use. Instead, access to cannabis-based products is left largely to individual states, with doctors typically offering “recommendations” rather than prescriptions. In contrast, Brazil’s regulatory approach, spearheaded by ANVISA, places clear authority in the hands of medical professionals to oversee cannabis-based treatments. ANVISA has established regulations that allow doctors to prescribe certain cannabis products for specific conditions. Since 2019, ANVISA has approved various cannabis-based medicinal products, though with strict guidelines. Brazilian regulations assume that physicians play a direct role in supervising patient use, aligning more closely with the structure used for conventional medications. This underscores a medicalized view where cannabis treatment requires the direct approval of a healthcare provider, reflecting the belief that all medications, including cannabis, should have formal oversight by trained professionals. The difference stems from both agencies’ distinct perspectives on cannabis's place in medicine. The FDA’s stance reflects longstanding federal policies that restrict cannabis due to its classification and the absence of FDA-approved clinical trials. As a result, U.S. doctors have less control over cannabis recommendations, limiting their role in dosage and treatment management. ANVISA, on the other hand, has taken a more progressive stance, focusing on regulated medical access through trained professionals, in part due to public pressure and growing recognition of cannabis’s therapeutic potential. This centralized and physician-led approach by ANVISA ensures that treatment aligns with Brazil's regulatory standards for medication, while also placing a high level of responsibility on healthcare providers to guide patients through cannabis use in a structured way. #MedicinalCannabis #CannabisRegulation #ANVISA #FDA #CannabisInMedicine #HealthcarePolicy #MedicalCannabis #CannabisBrasil #CannabisUSA #CannabisLaws #DoctorApproved #CannabisResearch

5

Have you met our incubated startup Indoor data? It's a top AI tool to manage and improve decisions for sports training. For more please connect with Bruno Silva and Bruno Travassos at UBImedical University of Beira Interior

3

Take a look👀 at the recent Research handbook on Entrepreneurial ecosystems, and at our chapter: "Do the human and social capital of startups matter for initial hiring decisions and survival? An empirical application to the Portuguese entrepreneurial ecosystem" Dina Pereira and João Leitão https://lnkd.in/dsdPPkcZ

15

2 comentários

📊#MarketRoundup: Brazil’s medicinal cannabis market is smoking hot Brazil’s medicinal cannabis market is set to expand by 22 percent this year, reaching a valuation of BRL 852 million (USD 142 million), according to a new report from market intelligence firm Kaya Mind. Patient boom. Around 672,000 patients in Brazil used cannabis-based products this year, a 50 percent increase from 2023. Nearly half accessed these products through legal import authorizations, primarily in the form of oils, gummies, and creams. State of play. Fewer than one-third of patients purchase cannabis products at pharmacies, where options are usually limited and prices significantly higher than imported alternatives. There are only about a dozen companies authorized to sell cannabis products in Brazil. Collective action. An additional 22 percent of people obtain cannabis-based products through patient and family collectives that start cultivating cannabis and producing their own medicine — at first, illegally, and later with court authorization. 🔗Read more in our full article by Letícia Arcoverde here 👇 https://lnkd.in/gupfhsDJ #Justice #Regulation #Cannabis #Business

6

Portugal has established itself as a leader in Europe’s medical cannabis sector, with over 60 companies currently authorised to grow, produce, and distribute cannabis-based products. https://lnkd.in/dRn9Y-Au

4

South Africa 🇿🇦 becomes the second largest importer into Australia for 2024. Interesting shake up form the Australian ODC data linked below. https://lnkd.in/dFKKrFsr From the data we can conclude: ✅ Canada still dominating the import of cannabis into Australia ✅ South Africa, Portugal, and Colombia as low-cost producers are slowly gaining traction as dominant suppliers - only a matter of time until quality becomes available in these countries such as Canada? ✅ High-cost countries such as Germany that lack scale slowly losing the export race? ✅ North Macedonia seeing the largest growth in 2023 ✅ Australian domestic production only grew by 7%, while the average amount of import from 2022 to 2023 grew by 69% ✅ 42.104 tonnes imported into Australia, while 26.593 being produced locally. In total, 68.697 tonnes imported and produced in Australia, demonstrating 60% import versus 40% domestic ✅ Germany is slowly not relying on Australia for imports directly with drop in exports, but New Zealand and UK becoming export focussed markets for Australia Proud of our country getting traction in the global medical cannabis world. LFG Saffas!! Please Springboks show us some good rugby this weekend in Brisbane!

85

5 comentários

FOR SALE - 🚀 Portuguese GACP cultivator & German GDP Distributor Package! 🚀   We’re excited to present a purpose-designed, wholly-owned, indoor licensed cultivation facility in Portugal! Sitting on ~3 hectares of land with a Phase 1 production capacity of 800 kg of premium dried flower annually, this facility is a turnkey solution for anyone looking to scale in the European market. Seeking outright divestiture of the wholly owned land and building, licences in Portugal and Germany, and going-concern business for just €4 million!   Key Highlights: Phase 2 Expansion: Ongoing construction of a 3,000 sq.m. high-tech cultivation facility + GMP certified processing and extraction site. Established Sales Channels: Active B2B sales with high-potency strains (up to 29% THC) registered and selling into Germany. Distribution Hub: Fully licensed in Germany with direct access to pharmacies. No Irradiation Required: Cultivated flowers are non-irradiated, enabling smoother sales cycles.   With a €4 million capital investment already made in the facility and land valued at €2.5 million, this is a rare chance to take over an operational and growing business in a market poised for expansion following Germany’s recent regulatory changes.   DM me or a member of the team for more info on this new opportunity! Pauline K Hyde Mike Samways Roshan Jesuthasan, (M.A.) Kieley Beaudry Andrew Kain Maria Daniele Samuel Meese Hyde Advisory & Investments Inc CannaNavigators Cannabis Global Consultants Inc. (CGC) Cannabis MarketSpace [email protected] www.hydeadvisory.com #cannabis #medicalcannabis #cannabisinvestment #cannabisindustry #cannabisnnews #cannabiscommunity #Portugalcannabis #cannabissector #cannabistransaction #cannabisbusiness #InvestmentOpportunity #BusinessForSale #EuropeanCannabis #PortugalBusiness #Germancannabis #MergersAndAcquisitions #cannabiscultivation #retailcannabis #cannabisproduction

56

Why relying on a brand with only 1 SKU isn't enough in competitive markets, and how we turned it around! We partnered with a distributor in Portugal, and initially, we only had one product under our brand in the market. The brand had sustainable growth, but there was potential for more. We wanted to optimize the market potential, but we knew expanding the product line was crucial to ensure long-term success. We realized that one product wasn’t enough to sustain growth or fully leverage our distribution. The market was competitive, and our partner needed more to stand out. Therefore, we took a bold step: launching a second product alongside the first. Time was of the essence, and execution had to be flawless. What if we could launch two products in the market in record time? What if both products could be on TV, rapidly increasing brand awareness and driving sales through our existing distribution network? Within two weeks, we finalised the artwork, prepared the packaging, and shipped the second product on time. Both products were on TV shortly after, boosting visibility and distribution. The result? We doubled the sales and market presence for both products. This case has now become a blueprint for future market expansions. If you’re looking to grow your portfolio and leverage smart strategies like this, let’s connect!

11

“Portugal is the number one infrastructure for cannabis in the entire EU. They have the most cultivations, which you need for manufacturing, they have a regulatory agency that's approving of us, and big companies paved the way to make things more efficient for companies like ourselves,” said Michael Sassano, the founder of SOMAÍ Pharmaceuticals. “We’re a global company and as countries develop, we plug into that. We are still waiting for Portugal but it's still a very small market compared to the biggest markets like Australia and Germany,” he said, adding “it's quite sad that the access isn't there for the medical patients, but I do believe that will pick up”. Read an insightful article by Aylin Elci in Euronews about the issues and hopes for medicinal cannabis in Portugal: https://lnkd.in/eYSmMUPM #SOMAÍ #GMP #medicalcannabis #biotechnology #medicalcannabismarket #manufacturing #pharmtech #medicalcannabisnews 

52

🇵🇹 In 2024, Portugal's startup landscape grew by 16%, with 4,719 companies generating a combined €2.6 billion in revenue. This growth, highlighted in a report by IDC, Informa D&B, and Startup Portugal, underscores the sector's role in the national economy. Startups account for 1.4% of Portugal's exports, with average monthly wages rising 17% to around €2,000 - significantly above the national average. 🔗 Know more 👉 https://lnkd.in/du4SjrJB #startupportugal #startup #startups #Portugal #PortugalMakesSense

6

Medicinal Cannabis in Brazil: A Promising Market that Brisa is Ready to Pioneer

5

🌿 Interested in breaking into the Portuguese cannabis market? Dive into our blog to uncover the essential steps to obtaining a cannabis license in Portugal! 💼 Plus, learn how GrowerIQ supports producers in navigating their market's regulations and requirements. Check it out now! 👇🚀 #CannabisLicensing #Portugal #GrowerIQ #CannabisIndustry #CannabisRegulations

5

According to a recent report from a market intelligence firm, Brazil's medical cannabis market is expected to grow by 22 percent this year, reaching a valuation of BRL 852 million (USD 142 million). https://lnkd.in/gupfhsDJ

1

The #WebSummit is on. Over 71,000 attendees, more than 1,000 investors and 3,000+ companies in #Lisbon showcasing the best of #technology. Presenting and discussing the major #tech trends. But above all, shouting out loud that #Portugal has definitely emerged as a major #TechHub in #Europe. Want to build a successful and innovative tech team? #InvestInPortugal

36

The authorisation of cannabis cultivation for industrial and medicinal purposes is indeed a major step forward for Brazil, offering real hope for patients who can benefit from cannabis-based treatments. However, such progress should ideally come directly from the Brazilian legislative branch. Unfortunately, the legislature has often been either silent on this issue or actively resistant to recognising the well-documented medicinal properties of cannabis, largely due to conservative stances and a tendency towards scientific denialism. This reluctance to embrace evidence-based healthcare reforms not only delays essential medical advancements but also disregards the needs of patients whose health and well-being could be greatly improved by these treatments. https://lnkd.in/dHyePJmR

2

Food for thought. Antonio Dias Martins from Startup Portugal shares his insights about the Portuguese ecosystem and what more can be done to improve it in a 3 part interview. One of those you can read it bellow. https://lnkd.in/d94KrZuQ

19

Lisbon is one of Europe’s leading startup capitals, often referred to as the "Startup Capital of Europe." Over the past decade, the city has transformed into a dynamic hub for technological innovation and entrepreneurship. Several key factors contribute to Lisbon’s rise as a global startup hotspot: 1. Global Tech Events Lisbon hosts the Web Summit, one of the largest and most influential tech conferences in the world. This annual event attracts entrepreneurs, investors, and industry leaders from across the globe, shining a spotlight on Lisbon as a thriving ecosystem for startups. 2. Government Support The Portuguese government actively promotes entrepreneurship through grants, tax incentives, and funding programs for startups and investors. Initiatives like the Startup Portugal Strategy have been instrumental in fostering a supportive environment for new businesses. 3. Affordable Cost of Living Compared to major European cities like London, Berlin, or Paris, Lisbon offers a significantly lower cost of living. This affordability extends to office space, salaries, and overall operational expenses, making it an attractive option for startups working with tight budgets. 4. Vibrant Startup Community Lisbon boasts a dynamic and collaborative startup ecosystem. The city is home to numerous coworking spaces, accelerators, and incubators, which provide resources, networking opportunities, and mentorship for entrepreneurs. Organizations such as Beta-i and Startup Lisboa play a pivotal role in supporting the growth of the local startup scene. 5. Talent Pool Portugal’s universities and technical institutions produce highly skilled graduates in technology, engineering, and business. Additionally, Lisbon’s quality of life and growing reputation as a tech hub attract international talent, creating a diverse and innovative workforce. 6. Strategic Location Lisbon’s geographical position on the western edge of Europe makes it a natural gateway to global markets. Its proximity to Africa and the Americas. 7. Cultural Appeal Lisbon’s warm climate, rich cultural heritage, and cosmopolitan lifestyle also contribute to its attractiveness for entrepreneurs and digital nomads. 8. Access to Funding In recent years, Lisbon has seen increased investment activity, with both local and international venture capital firms setting up shop in the city. The government has also introduced visa programs to attract foreign investors and highly skilled professionals. The Big Picture Lisbon’s combination of affordability, government support, and global connectivity has transformed it into a magnet for entrepreneurs. With a strong emphasis on community, innovation, and international collaboration, Lisbon is poised to remain a key player in the global startup ecosystem. #Startup #LisbonInnovation #WebSummit #Entrepreneurship #StartupEcosystem #LisbonTech #DigitalNomads #VentureCapital #GovernmentSupport #Coworking #Sustainable #InnovationCommunity #LisbonStartups

2